Navigation Links
Novavax Announces Early Retirement of $17 Million of Convertible Debt
Date:4/29/2009

Transaction removes significant financial obligation and improves balance sheet

ROCKVILLE, Md., April 29 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX), a leader in the development of novel vaccines, today announced that it has reached an early payoff agreement with holders of $17 million of the total $22 million in outstanding convertible notes. These convertible notes carried a coupon rate of 4.75% payable semi-annually and had a maturity date of July 15, 2009. Under the terms of the early retirement, the Company will pay 70% of the principal plus accrued and unpaid interest in cash and will issue shares of its common stock for the remaining 30% of the principal by dividing that principal amount by $2.50 for a total payment of approximately $12 million in cash and 2,040,000 shares of common stock. The remaining $5 million in outstanding convertible notes will be due on July 15, 2009 and can be paid in cash at maturity at the Company's option.

"The transaction announced today to retire $17 million of our outstanding convertible notes removes a significant financial overhang from the Company. We have taken the opportunity to repay a larger portion of this debt in cash than was initially anticipated based on our current resources and market conditions. Removal of this indebtedness will allow the Company to continue its primary focus on the core mission of developing important new vaccines that can make a significant impact on human health," stated Rahul Singhvi, President and Chief Executive Officer of Novavax, Inc.

About Novavax

Novavax, Inc. is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombina
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
2. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
3. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
4. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
5. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
6. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
7. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
8. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
9. Novavax CMO to Present at Phacilitate Vaccine Forum Washington 2009
10. NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate
11. Novavax to Present Seasonal Influenza Data Results in an Investor Conference Call on December 11, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... New York (PRWEB) May 22, 2013 ... the 3rd Annual Disruptive Innovations to Advance Clinical Trials ... Copley Plaza Hotel in Boston, MA. , Disruptive ... Janssen Pharmaceuticals and more share bold approaches to reduce ... , “Disruptive innovation needs to be big, or ...
(Date:5/22/2013)... Genedata, a leading provider of advanced ... life science research, today announced AB Enzymes will ... bioinformatics platform for strain genome data management on ... Enzymes, one of the world’s oldest and best-known ... Selector accompanied by bioinformatics consulting services. Genedata Selector, ...
(Date:5/22/2013)... Chicago, IL (PRWEB) May 22, 2013 Alton ... thetelegraph.com dated May 15, 2013 said that their presence ... help other bed bug sufferers avoid such big spending, My ... bugs inexpensively. , It was said in the report ... an exterminator, MCP related. Apart from that, its employees also ...
(Date:5/21/2013)... England , May 22, 2013 ... novel drug-only formulation of glycopyrronium bromide designed using Prosonix, ... pharmaceutical company developing a portfolio of inhaled Respiratory ... clinical study with PSX1002 that will assess its effect ... of doses in patients with moderate to severe chronic ...
Breaking Biology Technology:Disruptive Innovation Hits Clinical Trials, Dedicated Event Launches 2AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 2AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 3AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 4Bed Bugs Cost Alton Housing Authority $35,000; New Help, How to Kill Bed Bugs With Less Expense, Introduced by My Cleaning Products 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4
... ... Clinical Applications, BOTHELL, Wash., Nov. ... developer and marketer of proprietary,hypothermic storage and cryopreservation media products ... a Master File to the,United States Food and Drug Administration ...
... Nov. 5 On Friday, November 7, 2008,at ... members,of Cell Therapeutics, Inc.,s (CTI) (Nasdaq: CTIC ... conference call to discuss the Company,s 2008,third quarter ... Numbers Friday, November 7 8:30 a.m. ...
... Inc.,(Nasdaq: TELK ) reported a net loss of ... ended September 30, 2008, compared with a net loss ... period in 2007. The,$8.0 million net loss includes a ... with an auction reset feature, or,auction rate securities, which ...
Cached Biology Technology:BioLife Solutions Submits FDA Master File on HypoThermosol(R) Preservation and Storage Media for Cells, Tissues 2BioLife Solutions Submits FDA Master File on HypoThermosol(R) Preservation and Storage Media for Cells, Tissues 3Telik Announces Financial Results for 2008 Third Quarter 2Telik Announces Financial Results for 2008 Third Quarter 3Telik Announces Financial Results for 2008 Third Quarter 4
(Date:5/21/2013)... at USC have found that a class of pharmaceuticals ... , The drugs, known as "TSPO ligands," are ... looked at the effects of TSPO ligand in young ... and in aged mice when pathology was quite severe," ... School of Gerontology. "TSPO ligand reduced measures of pathology ...
(Date:5/21/2013)... COLUMBIA, Mo. Cancers of all types become most ... body. Once cancer has reached this stage, it becomes ... numerous tumors that can develop. Now, researchers at the ... radioactive nanoparticles that target lymphoma tumor cells wherever they ... professor of oncology in the MU College of Veterinary ...
(Date:5/21/2013)... Widely available in pharmacies and health stores, phosphatidylserine ... oysters, and soy. Proven to improve cognition and ... older people experiencing memory impairment. Now a team ... Bochner of Tel Aviv University,s Department of ... same supplement improves the functioning of genes involved ...
Breaking Biology News(10 mins):Drugs found to both prevent and treat Alzheimer's disease in mice 2MU researchers develop radioactive nanoparticles that target cancer cells 2Common food supplement fights degenerative brain disorders 2
... Wash. An international team of scientists from Italy, France, ... sequence of the domestic apple genome in the current issue ... genome sequence for apple will allow scientists to more rapidly ... which genes and gene variants provide disease or drought resistance ...
... a chronic and often disabling condition. Despite modern ... to the patients and their relatives and take ... and societal expenditure. The diagnosis of ... structure and changes in neurotransmission, with increased dopamine ...
... (August 27, 2010) Although having a high body ... cardiovascular disease, researchers are only beginning to understand how ... of the disease. Now, a study of a subset ... (KEEPS), suggests that as BMI increases, so do platelet ...
Cached Biology News:Core knowledge of tree fruit expands with apple genome sequencing 2Core knowledge of tree fruit expands with apple genome sequencing 3Body mass index and thrombogenic factors in newly menopausal women 2Body mass index and thrombogenic factors in newly menopausal women 3
... Ultra Agarose Spin Kit is an advanced system for ... purified DNA can be used directly for any downstream ... DNA is ready to use in 56 minutes ... used for TAE and TBE gels No specialised ...
... Kit has been designed for recovery of DNA from ... Features Ultra fast protocol: DNA is ready ... are easy to resuspend Bead uniformity prevents shearing ... (suitable for PCR) DNA is eluted into sterile ...
... DNA from agarose gels The SpinPrep Gel DNA ... bp to > 12,000 bp in size from agarose ... gel slice, followed by adsorption of the DNA to ... a wash step, the purified DNA is eluted in ...
BlotGel application pool -see Blotters (Semi-Dry) for more info...
Biology Products: